Tech Company Financing Transactions
Link Cell Therapies Funding Round
Link Cell Therapies, based in San Francisco, received $30 million from Johnson & Johnson Innovation, Bristol Myers Squibb and Kyowa Kirin.
Transaction Overview
Company Name
Announced On
9/29/2026
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Proceeds Purpose
The additional capital will support clinical and preclinical development of additional logic gated CAR-T programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
220 E. Grand Avenue
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Link Cell Therapies was launched by Stanford founders Robbie Majzner and Crystal Mackall in partnership with Samsara BioCapital to tackle one of the greatest challenges in cancer cell therapy -- the development of safe and effective CAR T agents for patients with solid tumors. Our unique logic-gate technology enables a new level of precision required for the safe deployment of CAR T beyond current indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Founder
Crystal Mackall
Founder
Robbie Majzner
Browse more venture capital transactions:
Prev: 9/29/2026: Reco venture capital transaction
Next: 9/29/2026: Rayon venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs